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A bstract: In this study, a series of com pounds derived from 4-m ethoxy-1H -isoindole-1,3(2H )-dione, 
potential ligands of phosphodiesterase 10A and serotonin receptors, w ere investigated as potential 
antipsychotics. A  library of 4-m ethoxy-1H -isoindole-1,3(2H )-dione derivatives w ith  various am ine 
m oieties w as synthesized and exam ined for their phosphodiesterase 10A (PD E10A )-inhibiting 
properties and their 5-H Txa and 5 -H T 7 receptor affinities. Based on in vitro studies, the m ost 
potent com pound, 18 (2-[4-(1H -benzim idazol-2-yl)butyl]-4-m ethoxy-1H -isoindole-1,3(2H )-dione), 
was selected and its safety in vitro was evaluated. In order to explain the binding mode of compound 
18 in the active site of the PDE10A enzym e and describe the molecular interactions responsible for its 
inhibition, com puter-aided docking studies w ere perform ed. The potential antipsychotic properties 
of com pound 18 in a behavioral m odel of schizophrenia w ere also investigated.
K eyw ords: benzim idazole derivatives; phosphodiesterase 10A; schizophrenia; antipsychotic activity
1. Introduction
Isoindole-1,3-diones (phthalim ides) and their N-substituted analogs have been a very interesting
and topical research area due to their w ide structural diversity and broad-spectrum biological activities. 
The sulphonamide and amide derivatives of N-phenyl-phthalimide (compounds 3a-e  and 4a-e, Figure 1)
displayed potent inhibitory activity on neutrophil recruitment, which correlated with their inhibitory effect
on tumor necrosis factor a  (TNF-a) level [1]. N-1-Adamantyl-4-aminophthalimide (compound 2 ', Figure 1) 
exhibits anti-HIV-1 and anti-HIV-2 activity in CEM  cell cultures [2]. The N -pyridinyl and N-quinolinyl 
substituted derivatives of phthalimides (compounds 8 '  and 12 ', Figure 1) demonstrated cytotoxicity against 
the growth of a num ber of cultured cell-lines [3] . 1,3-Dioxoisoindoline-5-carboxamides (compound 4d ',
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Figure 1) are potent T-type calcium  channel blockers [4], whereas 1,3-dioxoisoindoline-5-carboxylic 
acid derivatives (com pounds 2c' and 3 c ', Figure 1) are potent xanthine oxidase inhibitors [5]. 
Moreover, (ZE)-2-[4-(1-hydrazono-ethyl)phenyl]isoindoline-1,3-dione (com pound 12 ', Figure 1) has 
shown remarkable anti-microbial activity [6 ]. In the central nervous system (CNS), N-phenylphthalimide 
derivatives (ADD213063 and A D D219048, Figure 1) have exhibited original anticonvulsant 
properties [7]. Pazinaclone (DN-2327, Figure 1) produces sedative and anxiolytic effects by  acting 
as a partial agonist of G A BA A benzodiazepine receptors [8 ]. Potent acetylcholinesterase inhibitors 
(AChEIs) w ere identified in a group of 2-fluorinated-benzylam ino-alkyl-isoindoline-1,3-diones [9], 
2-(benzylam ino-2-hydroxyalkyl)isoindoline-1,3-diones [10] (com pounds 6 ' and 12', Figure 1) and 
2-(2-(4-benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione (com pound 4 e ', Figure 1) derivatives [11]. 
N AN -190 (2-m ethoxyphenyl)-4-(4-phthalim idobutyl)piperazine, Figure 2) is a selective antagonist of 
serotonin 1A subtype receptors (5-HT1ARs) that potently blocks the alfa 2 adrenergic receptor (a 2ARs) [12].
Figure 1. Examples of phthalimide derivatives with various biological activity [1- 12].
Schizophrenia is a m ultifactorial m ental illness that affects 1% of the population. Both genetic 
and environm ental contributions play an im portant role in  the m anifestation of a w ide range of 
behavioral, em otional, and cognitive abnorm alities in  schizophrenia. Since the introduction of 
chlorprom azine, clinical practice has relied upon antipsychotic drugs (APDs) over the past half 
century, w ith  num erous first-, second-, and third-generation antipsychotics discovered during this 
tim e. Typical, or first-generation, A PD s (chlorprom azine and haloperidol) exhibited high-affinity 
dopam ine D 2 receptor antagonism , w hich causes both  antipsychotic actions and m any side effects 
e.g., extrapyram idal and endocrine. Atypical, or second generation, antipsychotics (SGAs) were then 
developed to avoid the extrapyram idal side effects. SG A s include com pounds such as clozapine, 
o lanzapine, and quetiapine that exhibit relatively m oderate affinity for D 2 and 5-H T2A receptors or 
drugs like risperidone that effectively block both serotonin 5-H T2a  and dopamine D2 receptors [13,14]. 
The first representative of the third generation of APDs was aripiprazole, w hose m echanism  of action 
w as ascribed to partial agonism  of D 2 . A lthough aripiprazole has effects on several other receptors, 
this drug is the first "dopam ine stabilizer" based on D 2 partial agonist properties. However, the data 
available on the m echanism  of action of aripiprazole are inconsistent with a mode of action related to the 
partial agonism of D2 . Therefore, a recent hypothesis regarding the functional selectivity of aripiprazole 
for D 2 has em erged that seems to describe its m echanism  of action more accurately [15,16]. Although 
all approved antipsychotic drugs show  affinity for dopam ine D 2 receptors, there is evidence that 
m odulation of the serotonergic system leads to enhanced antipsychotic therapy [17,18]. Partial agonism
of 5-H Txa, and antagonism  of 5-H T2A, 5-H T 6, and 5-H T7 receptors, contributes to a reduced risk 
of extrapyram idal side effects and im proved specific cognition dom ains of atypical antipsychotic 
drugs [14].
The phosphodiesterase 10A (PD E10A) enzym e is highly expressed in the striatal m edium  spiny 
neurons (MSNs), w here it m odulates both dopam ine D2- and Dx-dependent signaling. Striatal M SNs 
pathw ays are divided into d irect dopam ine D 1 receptor-m ediated and indirect dopam ine D 2 
receptor-m ediated striatal output pathways [19]. Dopam ine D 1 receptors in direct pathway M SNs are 
coupled with Gs proteins, which activate adenylate cyclase to increase cyclic adenosine monophosphate 
(cAMP) concentration, whereas the stim ulation of D2 receptors inhibits the activity of adenylyl cyclase, 
resulting in a decrease in the level of cAMP. On the other hand, inhibition of PDE10A in the dendritic 
m em branes of M SN s results in  suppression of D 2-m ediated signaling, w hich  is sim ilar to the effects 
of D 2 antagonists. U pregulation of cyclic nucleotide levels in  ind irect pathw ay M SN s could be an 
alternative approach for novel antipsychotics [20,21], w hereas activation of d irect pathw ay M SN s 
could be associated w ith  im provem ent of cognitive functions. Thus, in contrast to the m arketed 
antipsychotics, phosphodiesterase inhibitors (PDEIs) influence both the indirect and direct pathways, 
and the additional action of these com pounds on the d irect pathw ay could help distinguish them  
clinically  from  D 2 antagonists [2 2 ] . M oreover, PD EIs m ay have potential therapeutic u tility  in  the 
treatm ent of cognitive im pairm ent associated w ith  schizophrenia or m ay be useful as an adjunctive 
treatm ent for negative sym ptom s in patients w ith schizophrenia [19].
In complex diseases such as schizophrenia, single-target drugs have turned out as failures, whereas 
multi-target drugs have been found to be m uch more efficacious. In clinical practice, many combinations 
of psychotropics have been  tried for schizophrenia, based on a trial-and-error paradigm  guided by 
clinical experience and patient response. A n overall superior and safer solution seem s to be the 
m odern concept of designer m u ltiple-targeting ligands (D M Ls). The D M Ls are also described as 
"polypharm acology by design", w hich claims parallel m odulation of defined m ultiple biological targets 
by  designer sm all m olecule drugs [23]. A n exem plification of this idea is atypical antipsychotics, 
w hich target a num ber of G  protein-coupled receptors (GPC Rs) sim ultaneously. Currently, novel 
strategies in designing drugs effective in  treatm ent of schizophrenia focus on  targets beyond the 
dopam inergic hypothesis of the disease [24].
In  order to search for novel potential antipsychotic agents, w e rationally  synthesized a 
series of N -substituted isoindole-1,3-d ione derivatives, w hich  w ere designed to in teract w ith  the 
serotonin 5 -H T 1a / 5 -H T7 receptor and/or inhibit PD E10A . The core 1H -isoindole-1,3(2H )-dione 
m oiety  w as selected from  the structure of the 5-H TlA antagonist, N A N -190 (Figure 2 ). N ext, 
a m ethoxy m oiety  w as introduced at position 4 of the isoindole-1,3-d ione so as to be able to 
obtain  structural analogs o f PD E10A Is (com pound B-3, Figure 2 ) [25]. The isoindole-1,3-d ione 
core w as connected  by  one to five m ethylene linkers w ith  am ines. For determ ining the im pact of 
N -alkylam ine substitution of isoindole-1,3-d ione on 5-H TR  affinity and PD E10A  inhibitory activity, 
different heterocyclic am ine substituents w ere investigated. M odifications of am ine substituents 
com prised changes in  the size of the heterocyclic am ine ring from  1H -im idazole and pyridine, 
to benzim idazole, 6 ,7-d im ethoxy-1,2,3,4-tetrahydro-isoquinoline, 1 ,2,3,4-tetrahydroisoquinoline, 
and the decahydroisoquinoline moiety. Previously, these am ines w ere used in  the design of potent 
5 -H T1A and 5-H T7 ligands (compound 18 and PZ-376, Figure 2 ) [26- 28], and they are partially saturated 
analogs of isoquinoline, w hich  is present in the structure of papaverine, a potent PD E10A  inhibitor. 
M oreover, the benzim idazole m oiety can be found in  the structure of num erous PD E  inhibitors and 
serotonin ligands (com pound 10, Figure 2 ) [29,30]. Finally, a phenyl ring w as chosen instead of a 
heterocyclic am ine group in order to exam ine the effect of am ine substitution on  selected 5-H TRs 
affinity and PDE10A inhibitory activity.
Figure 2. General structure of novel compounds 3-23, designed based on potent phosphodiesterase 
10A (PDE10) inhibitors and active serotonin receptor ligands [20,25,26,28- 30]. The phthalimide cores 
and amine groups are highlighted in blue and green, respectively.
The series of designed ligands w ere synthesized and evaluated in adequate biological assays, 
a lum inescence PD E inhibition assay, as w ell as a radioligand binding assay for 5-H T 1a  and 5-H T 7 
receptors. Computer-aided studies were undertaken to identify the structural elements responsible for 
in  vitro activity. Finally, for the m ost active com pound, C om pound 18, in  vitro safety studies w ere 
perform ed and prelim inary in vivo activity was tested in an anim al m odel of schizophrenia.
2 . R esu lts and D iscu ssion
2.1. Chemistry
The series of rationally designed 4-m ethoxy-1H -isoindole-1,3(2H )-dione derivatives (3-23) were 
synthesized in average to good yields (30-75% ), as shown in Scheme 1. The starting 2,3-dim ethylphenyl 
m ethyl ether (1) w as synthesized by  a procedure published elsew here [31]. The interm ediate 
com pound, 4-m ethoxy-2-benzofuran-1,3-d ione (2 ), w as obtained from  1, according to a previously  
described procedure [32] w ith  slight m odifications. The am inoalkylam ine m oieties derived from  
6,7-dim ethoxy-1,2,3,4-tetrahydroisoquinoline, 1,2,3,4-tetrahydroisoquinoline, decahydroisoquinoline, 
and 1H -1,3-benzodiazole w ere obtained in line w ith the earlier reported m ethods (Schem e 2) [33,34], 
w hile those containing 1H-im idazole, pyridine, and phenyl rings w ere com m ercially available.
Scheme 1. Reagents and conditions of the chemical synthesis route: (a) CH3I, K2CO3, DMF, 75 0C, 12 h; 
(b) KMnO4, H2O/tBuOH, reflux, 12 h; AcOH, THF, reflux, 4 h; (c1) appropriate amine, AcOH, reflux, 
48 h; (c2) appropriate amine, TEA, 4A molecular sieves, toluene, reflux, 16 h. 2,3-Dimethylphenol and 
phthalic anhydride were commercially available.
Scheme 2. Reagents and conditions of the chemical substitution routes: (a) appropriate amine, 
N-bromoalkylphthalimide, K2CO3, MeCN, reflux, 12 h; 40% CH3NH2, 20% NaOH, room temperature, 
2 h; (b) appropriate amino acid, 1,2-phenylendiamine, 4N HCl, microwave heating, 100 0C, 40 min [33,34].
2.2. In Vitro A ctivity o f  Compounds 3 -23
2.2.1. PDE10A Inhibitory Activity
The novel series of compounds w as derived from a 4-methoxy-2,3-dihydro-1H-isoindole-1,3-dione 
(4-methoxyphthalimide, Figure 1) fragment, w hich was connected via different lengths of a carbon-chain 
linker (C 1- C 5) to various am ine fragm ents (e.g., 6 ,7-d im ethoxy-1,2,3,4-tetrahydroisoquinoline; 
1H -im idazole; 1 ,2,3,4-tetrahydroisoquinoline; 1H -benzim idazole; and decahydroisoquinoline) or 
to a phenyl ring (3-17). In this series, seven com pounds (7, 8 , 11, 12, 15-17) displayed PD E10A  
inhibitory activity  in the lum inescence PDE inhibition assay  a t a concentration of 10 gM  (7-92% , 
Table 1). Furtherm ore, four analogs o f the m ost prom ising 4-m ethoxyphthalim ide derivatives 
(1 5 ,1 7 -1 9 ), containing the phthalim ide moiety, w ere synthesized (20-23). A m ong them , three of the 
four phthalim ide derivatives (21-23) show ed m oderate activity tow ard PDE10A (45-73% , Table 1).
Table 1. Screening data from a luminescence PDE inhibition assay and a radioligand binding assay 
for 5-HTja and 5-HT7 (%) of 4-methoxy-1H-isoindole-1,3(2H)-dione and 1H-isoindole-1,3(2H)-dione 
derivatives displaying phosphodiesterase 10A inhibitory activity and binding affinity for serotonin 
5-HTja and 5-HT7 receptors as well as selected IC50 values of the most active compounds for PDE10A.
Compd R n
PDE10A [% ]1 IC50 PDE10A 5-HT1A 5-HT7
10 pM 3 pM [pM] ± SEM 3 1 pM 2 ± SEM 3
3 A 2 0 0 - 27 ± 3 0 ± 0
4 B 2 0 0 - 12 ± 4 0 ± 0
5 C 2 0 0 - 25 ± 3 0 ± 0
6 A 3 0 0 - 32 ± 4 0 ± 0
7 B 3 19 18 - 33 ± 2 51 ± 2
8 C 3 7 7 - 28 ± 3 0 ± 0
9 D 1 0 0 - 6 ± 2 0 ± 0
10 E 1 0 0 - 10 ± 1 0 ± 2
11 F 1 15 7 - 39 ± 3 0 ± 1
12 D 2 10 5 - 13 ± 2 0 ± 0
13 E 2 0 0 - 59 ± 4 0 ± 2
14 G 2 0 0 - 21 ± 1 0 ± 0
15 F 2 70 40 6.710 ± 0.195 44 ± 5 0 ± 3
16 D 3 13 11 - 32 ± 3 1 4 ± 0
17 F 3 86 73 1.001 ± 0.009 16 ± 5 10 ± 3
00 F 4 92 79 0.886 ± 0.017 28 ± 3 3 ± 1
19 F 5 75 52 4.305 ± 0.365 28 ± 2 6 ± 0
20 F 2 1 0 - 26 ± 2 36 ± 0
21 F 3 45 16 - 27 ± 2 1 4 ± 2
22 F 4 73 47 5.645 ± 0.495 20 ± 3 15 ± 2




75 54 5.755 0.055
100 ±  0 99 ± 1
0 0
1 The percentage of inhibition was calculated respective to vehicle control (DMSO); A: 6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline, B: 1,2,3,4-tetrahydroisoquinoline, C: decahydroisoquinoline, D: phenyl, E: 2-pyridine,
F: 2-benzimidazole, G: 1H-imidazole; 2 % of control specific binding; 3 SEM of three independent experiments 
performed in duplicate; 4 Additionally, the percent of inhibition of the control binding for 5-HT2A and D2 for 
compound 18 were evaluated. The screening results were 8.8% and 0%, for 5-HT2a  and for D2 receptors, respectively, 
at a concentration of 1 gM. The screening tests for 5-HT2a  and D2 receptors were performed in the CEREP 
Laboratories, France—Eurofins Scientific (www.cerep.fr).
Initially, am ong com pounds w ith  a linker length of one to three m ethylene units (3-17), 
the highest percentage of PD E10A  inhibition (70-86% ) w as exhibited by com pounds containing 
the 1H-benzimidazole m oiety (15,17). Therefore, the influence of the length of the linker on inhibition 
of PD E10A  w as investigated in this group of com pounds. In the case of the 1H -benzim idazole
containing com pounds, 11, 15, and 17-19 , the elongation of the linker from  one to five m ethylene 
groups resulted in an increase and then a decrease in  the inhibition of PD E10A . The m ost active 
com pound am ong them , com pound 18 (92% inhibition), has a linker of four m ethylene units that 
connects the 4-m ethoxyphthalim ide fragm ent w ith the 1H-benzim idazole moiety. The m odifications 
of the 1H -benzim idazole moiety, such as replacem ent w ith 1,2,3,4-tetrahydroisoquinoline fragm ent 
(4, 7), or its saturation (8 vs. 7), as w ell as rem oval of one arom atic ring in this part (10, 13, 14) 
decreased the observed affinity to PDE10A. Interestingly, com pounds 12 and 16, containing a phenyl 
moiety at the terminal location, despite the lack of a functional amine group, showed very low activity 
toward PDE10A.
In addition, the relevance of the introduction of a 4-m ethoxyl group to the 4-m ethoxy-2,3-dihydro- 
1H-isoindole-1,3-dione fragm ent was also verified. For this purpose, a small phthalim ide series w ithout 
a 4-m ethoxy group at position 4 (Table 1) connected via an alkylene linker to the 1H -benzim idazole 
m oiety (20-23) was synthesized. The activity of compounds 20-23  was significantly lower than that of 
their 4-m ethoxy analogs (15 ,17 -19 ). Moreover, sim ilar to the 4-m ethoxy series, the inhibitory activity 
of com pounds 20-23  increased w ith  the length of the linker up to four m ethylene units and then 
slightly decreased.
In the next step, the five m ost active com pounds chosen (15, 17-19 , 22 ) w ere quantitatively  
tested in  the lum inescence PDE inhibition assay, alongside papaverine as the reference drug. 
The effectiveness of inhibition was expressed as the half m axim al inhibitory concentration (IC50) values. 
The chosen com pounds displayed a percentage of inhibition above 70% at the concentration of 10 pM. 
All investigated compounds (1 5 ,1 7 -1 9 ,22 ) displayed satisfactory IC50 values (886  nM -6.71 pM, Table 1 
and Figure 3) in comparison with papaverine (5.755 pM). It is noteworthy that the most potent PDE10A 
inhibitor, com pound 18 (IC50 =  886  nM ), w as in-line w ith  the predictions stipulated by Lipinski's 
Rule of Five, w hich describes "dru g-like" param eters of small m olecules in terms of lipophilicity, size, 
polarity, solubility, flexibility, and saturation [35] (see graph, Figure S1, in Supporting M aterials).
INHIBITION OF PDE10A ENZYME
log [compounds] (M)
Figure 3. Dose-response curve of the most active compounds 15, 17, 18, 19, 22 and reference 
drug-papaverine on PDE 10A activity measured by the luminescence method.
2.2.2. Serotonin Receptor Affinity
In the next phase of the current study, the binding affinities of novel 4-m ethoxy-2,3-d ihydro- 
1H-isoindole-1,3-dione derivatives for 5-H T1a  and 5-H T7 receptors w ere determ ined in a radioligand 
binding assay (Table 1). The results revealed that the m ajority of the tested compounds displayed very 
low -to-m oderate affinity for the 5-H T1A receptor (6-59% ) at a concentration of 1 pM, but only a few 
show ed any affinity for the 5-H T 7 receptor (7 ,1 6 -2 3 ). The highest 5-H T1a  or 5-H T 7 receptor affinity 
w as observed for com pounds 13 (59% for 5-H T 1a ) and 7 (51% for 5-H T 7), respectively. A m ong the 
investigated series, three com pounds (7, 20, and 23) show ed a low  bu t significant (above 20%) 
percentage of binding for both  5-H T 1A and 5-H T 7 receptors (33%, 26% , 48%  and 51% , 36% , 34% , 
respectively).
In sum m ary, the present study determ ined that the m ajority  of the 2,3-dihydro-1H -isoindole-
1,3-dione derivatives (3-23) show ed affinity tow ard the 5-H T 1A receptor, w hereas only few  bind 
at the 5-H T 7 receptor site. In  the case of 1H -benzim idazole derivatives (com pounds 15, 17-19), 
w hich significantly  inhibited PD E10A  (IC50 =  886  n M -6.71  pM), low  affinity for 5-H T 1A receptors 
(16-44% ), and even low er for 5-H T7 receptors (0-10% ) was observed.
Furtherm ore, because com pound 18 contains structural m oieties such as benzim idazole and 
phthalim ide, w hich are also present in serotonin 5-H T2a  and dopam ine D 2 receptor antagonists [14], 
it was decided to test the affinity of Com pound 18 to these receptors. The obtained results (appendix 
below  Table 1) revealed that at a concentration of 1 pM com pound 18 displayed negligible percentage 
of binding for 5-H T2a  and none for D 2 receptors (8 .8% and 0 %, respectively).
2.3. M olecular M odeling Studies
In line w ith  in vitro results, the m ost active 4-m ethoxy-2,3-d ihydro-1H -isoindole-1,3-dione 
derivative w ith a bezim idazol-2-yl butyl moiety (18) was selected to clarify and draw useful information 
regarding the nature of the interactions of PDE10A with its ligands, and insights into structure-activity 
relationships w ere investigated. We elucidated putative binding m odes of several derivatives 
throughout the process of docking to the protein target, w hich was represented by the optimized crystal 
structure of the studied enzyme. As a representative example, binding interactions were presented for 
com pound 18 (2-[4-(1H -1,3-benzodiazol-2-yl)butyl]-4-m ethoxy-2,3-dihydro-1H -isoindole-1,3-dione) 
(Figure 4 ).
Figure 4. The predicted binding mode of compound 18 in the active site of phosphodiesterase 10A 
(PDB ID: 3SNI). Crucial interactions of the compound in the catalytic site with Gln716 and Phe719, 
as well as its positioning in the selectivity pocket (Tyr683) predict inhibitory activity of the series of 
rationally-designed derivatives synthesized in this study. Amino acid residues engaged in ligand 
binding (within 4 A from the ligand atoms) are displayed as sticks, whereas crucial residues, e.g., forming 
H-bonds (dotted yellow lines) or n-n stacking (dotted cyan lines), are represented as thick sticks.
The 2,3-dihydro-1H -isoindole-1,3-dione moiety, bound in the catalytic active site, interacted with 
G ln716 (H -bond) and w ith  Phe719 (n-n  stacking). In  the case of the m ost active com pound (18), 
the 4-m ethoxy group acted as the H-bond acceptor, whereas unsubstituted analogs interacted through 
the carbonyl group of the im ide moiety. The oxygen atom  of the phthalim ide was less electronegative 
than the one of the m ethoxy group, thus m aking the H -bond accepting properties w eaker and
disadvantageous in comparison with that of the 4-m ethoxy-substituted analogs. Moreover, the H-bond 
form ed by the latter group attracted the heteroaryl ring of the ligand closer to Phe719/686, thereby 
facilitating the n -n  interaction in the hydrophobic clamp. The 1H-1,3-benzodiazole fragm ent accepted 
the H -bond from  Tyr683 in the selectivity pocket. The interaction w as secured by the optim al length 
of the linker— 4 carbon atom s and resulted in favorable scoring function value -8 .8 8 5  (glide gscore) 
(Figure 4 ) . Both longer and shorter aliphatic chains decreased the inhibitory potential (see Table 1), 
enforcing suboptimal arrangement of the terminal moieties in the active site, w hich resulted in the loss 
of one of the aforem entioned key interactions (e.g., in the case of com pound 19) or decrease in scoring 
function value (-8 .2 5 4  for com pound 15).
2.4. Cytotoxicity
In the subsequent stage of the study, the safety profile of the m ost active com pound, 18, 
w as analyzed. Such analysis requires the exclusion of adverse effects of organ toxicity  before 
proceeding to further in vivo studies. A ccording to the guidelines for the study of biologically active 
m olecules, cell lines are a good alternative to animal models at the initial stage of the drug cytotoxicity 
evaluation process. The two cell lines used in this study, namely, the SHSY-5Y and HepG2 cell lines are 
approved in vitro m odels, w hich can be used to obtain prelim inary results regarding possible neuro- 
and hepato-toxicity [36].
The M TT assay, w hich m easures the m etabolic status of cells, was used to determ ine cytotoxicity. 
The results of the experim ents clearly  indicate that com pound 18 is safe. D ecreasing cell viability  
(H epG2/SH SY-5Y) is observed only at h igher concentrations of com pound 18, w hile the reference 
standard, doxorubicin (DOX), a w ell-described cytotoxic agent, dem onstrated significantly decreased 
cell viability already at m uch low er concentrations (Figure 5) .
Figure 5. Viability of SHSY-5Y and HepG2 cells treated with compound 18 in the MTT test; doxorubicin 
(DOX) was used as reference control. (A): compound 18 (SHSY-5Y), (B): DOX (SHSY-5Y), (C): compound 
18 (HepG2), (D): DOX (HepG2). Graphs represent the viability of cells as a % of control (non-treated 
cells). Values represent means ± SEM of three independent experiments. Statistical significance (*) vs. 
control was determined using the Mann-Whitney test, p <  0.05.
2.5. Behavioral Evaluation
For further behavioral characterization, com pound 18, w ith  the highest PD E10A  inhibitory 
activity and satisfactory cytotoxicity  profile, w as selected. Thus, the potential antipsychotic 
properties of com pound 18 as an inhibitory effect on PD E10A  in a behavioral anim al m odel w as 
determ ined. The obtained results revealed that treatm ent of m ice w ith  d-am phetam ine (AM PH ) 
significantly increased horizontal locom otor activity throughout the duration of the test. Papaverine 
dose-dependently  antagonized this response at both  tested doses of 40 and 60 m g/kg for 60 min. 
Com pound 18 adm inistered at a dose of 60 m g/kg decreased A M PH -induced hyperactivity, but only 
for the first 10 m in after injection (Figure 6 ) . The low er doses of com pound 18, as w ell as papaverine, 
did not change the stim ulating effect of A M PH  (data not show n). To assess if a nonspecific 
suppression of locom otion contributes to the ability of the tested compounds to oppose AM PH-induced 
hyperactivity, the influence of these com pounds on spontaneous locom otor activity  w as m easured. 
The locom otor-suppressing effects w ere observed after the adm inistration of papaverine (40 and 
60 mg/kg) as w ell as 18 (60 mg/kg) (see Table S1 in Supporting M aterials).
vehicle i I papaverine 40 mg E X X ] 18 60 mg ixmxxi
AMPH 2.5 mg i I papaverine 60 mg kwwws
Figure 6. Effects of papaverine and compound 18 on d-amphetamine-induced hyperlocomotor activity 
in CD-1 mice. Data are expressed as the mean of the number of movements recorded after 10, 20, 30, 
and 60 min of the papaverine-treated groups (at doses of 40 and 60 mg, respectively) and the compound 
18-treated group (at a dose of 60 mg) ± S.E.M. * p <  0.05, ** p <  0.01, **** p <  0.0001, versus the respective 
vehicle-treated group, ~  p <  0.01, p <  0.001, p <  0.0001, and versus the respective AMPH-treated 
group (one way ANOVA followed by Bonferroni's post-hoc test). AMPH-d-amphetamine.
In sum m ary, the suppression of A M PH -induced hyperlocom otion suggests antipsychotic-like 
properties of com pound 18, as w ell as of papaverine. H ow ever, these effects are transient and m ay 
only reflect the decrease in spontaneous locom otor activity. Our findings are consistent w ith previous 
studies conducted w ith  papaverine in  rats [19,37], show ing that the period of papaverine-induced 
suppression of spontaneous locom otor activity fully included tim e of reversal of hyperlocom otion 
produced by AM PH injection. Similar findings are reported by Schmidt et al. [38 ] for compound TP-10, 
which is a PDE-10 inhibitor with im proved potency and selectivity. The aforementioned results suggest 
that antipsychotic-like properties of PDE10A inhibitors detected with locomotor-based paradigm s need 
to be treated w ith caution, due to concurrent inhibition of spontaneous locom otor activity. M oreover, 
at this stage of our preliminary study, we can only speculate that the cause of compound 1 8 's transient 
effect on A M PH -induced hyperlocom otor activity m ay be a result of either rapid redistribution to 
the other brain  structures or rapid m etabolism . In order to overcom e possible pharm acokinetic and
m etabolic stability problem s, w e plan to further optim ize the leading structure of com pound 18 and 
conduct extended in vitro and in vivo investigations.
3. M aterials and M ethods
3.1. Chemistry
A ll chem icals and solvents w ere purchased from  com m ercial suppliers (A ldrich, Poznań, 
Poland and Chem pur, P iekary Śląskie, Poland) and w ere used w ithou t further purification. 
M elting  points w ere m easured in open capillaries on an  E lectrotherm al 9300 apparatus. Thin-layer 
chrom atography (TLC) w as run on M erck silica gel 60 F254 a lum inium  sheets (M erck; D arm stadt, 
G erm any), using the follow ing m ixtures of solvents: (S1) d ichlorom ethane (9)/m ethanol (0.3), 
(S2) d ichlorom ethane (9)/m ethanol (0.7), (S3) d ichlorom ethane (9)/m ethanol (1). A nalytical H PLC 
w as conducted on a W aters H PLC  instrum ent w ith  a W aters 485 Tunable A bsorbance D etector UV, 
equipped with a Sym etry colum n (C18, 3.5 gm, 4.6 X 30 mm) using a water/acetonitrile gradient with 
0.1% trifluoroacetic acid (TFA) as the m obile phase at a flow rate of 5 mL/min.
Additionally, the liquid chrom atography/m ass spectrom etry (LC/MS) analysis was perform ed on 
a W aters A cquity TQ D  system , w ith  a W aters TQ D  quadrupole m ass spectrom eter w ith detection by 
UV (DAD) using an Acquity UPLC BEH C18 colum n (1.7 gm, 2.1 mm X 100 mm). A water/acetomtrile 
gradient w ith  0.1%  TFA w as used as a m obile phase at a flow  rate of 0.3 m L/m in. The U PLC/M S 
purity of the investigated  com pounds (3 -23) proved to be over 98% . N M R  spectra w ere recorded 
on a Varian M ercury 300 M H z spectrom eter (Varian Inc., Palo A lto, C A , U SA ) u sing the solvent 
(CDCl3 or D M SO -d6) signal as an internal standard; chem ical shifts are expressed in parts per m illion 
(ppm). Signal multiplets are represented by the following abbreviations: s (singlet), brs (broad singlet), 
d (doublet), t (triplet), m (m ultiplet).
3.1.1. General Procedure for Synthesis of 4-M ethoxy-2-benzofuran-1,3-dione (2)
The 4-m ethoxy-2-benzofuran-1,3-dione was obtained from 1, according to a previously published 
procedure [32], w ith slight modifications. Briefly, 2,3-dim ethylphenyl methyl ether (3.4 g, 25 mmol) was 
dissolved in w ater (98 mL) and tert-butanol (42 mL). After potassium  perm anganate (25 g, 160 mmol) 
w as added, the reaction m ixture w as refluxed for 12 h. The resulting suspension w as filtered over 
C elite, concentrated to 50 m L, acidified w ith  37%  hydrochloric acid, and left standing overnight at 
room  tem perature. The 3-m ethoxybenzene-1,2-dicarboxylic acid crystallized as a w hite solid (4.34 g) 
and w as refluxed for 4 h in anhydrous tetrahydrofuran (24 mL) w ith the addition of acetic anhydride 
(7 m L). U pon cooling to room  tem perature, the reaction m ixture w as concentrated in vacuo and the 
white solid was dried at 50 °C for 48 h, to afford 4-m ethoxy-2-benzofuran-1,3-dione (3.82,97% ). HPLC: 
Rt =  0.931, MS calcd for [M +  H]+: C9H6O4 m/z: 178.14, found: 178.97; XH -N M R (300 M Hz, DMSO-d6) 
6 ppm  3.99 (s, 3 H) 7.59 (dd, J  =  9.67, 7.91 Hz, 2 H) 7 .90-7 .97 (m, 1 H).
3.1.2. General Procedure for Synthesis of the Final Series of Com pounds (3-23)
The final compounds (3-23) were obtained w ithin two different pathways, described in procedures 
A  and B. Procedure A  (3 -5 , 9 ,1 2 ,1 6 ) : a stoichiom etric am ount of 4-m ethoxy-2-benzofuran-1,3-dione 
(0.196 g, 1.1 m m ol) and appropriate am ine (1.1 m m ol) in  g lacial acetic acid (2 m L) w as refluxed for 
48 h, w ith  stirring. U pon cooling to room  tem perature, the reaction m ixture w as extracted w ith  
diethyl ether and concentrated in vacuum  [39]. Procedure B (6- 8 ,1 0 ,1 1 ,1 3 -1 5 ,1 7 -2 3 ) :  an am ount of 
4-m ethoxy-2-benzofuran-1,3-dione (0.178 g, 1.0 m m ol), along w ith specific am ounts of an appropriate 
am ine (1.2 m m ol), trim ethylam ine (0.28 m L, 2 m m ol), and 4 A m olecular sieves w ere added in 
anhydrous toluene (4 m L) and the m ixture w as refluxed and stirred overnight. The reaction m ixture 
was then filtered and the solvent w as evaporated in vacuum  [40]. All the final compounds (3-23) were 
purified by colum n chrom atography using dichlorom ethane (9)/m ethanol (0.7) as eluent.
2-[2-(6,7-Dim ethoxy-3,4-dihydroisoquinolin-2(1H )-yl)ethyl]-4-m ethoxy-1H-isoindole-1,3(2H)-dione (3)
Yellow  pow dery crystals. Yield: 42% ; m p 108-109  °C; TLC: R f =  0.44 (S i); H PLC: tR =  0.979; 
M S calcd for [M +  H ]+: C22H24N 2O5 m/z: 396.17, found: 397.16; 1H -N M R (300 M Hz, CDCl3-d) 6 ppm
2 .72-2 .82  (m , 6  H) 3.62 (s, 2 H) 3 .78-3 .82  (s, 6  H) 3 .84-3 .90  (m, 2 H) 3.99 (s, 3 H) 6.52 (d, J  =  16.16 Hz, 
2 H) 7.12-7.20 (m, 1 H) 7.34-7 .43 (m, 1 H) 7.61 (dd, J  =  8.46, 7.44 Hz, 1 H).
2-[2-(3,4-D ihydroisoqum olm -2(1H )-yl)ethyl]-4-m ethoxy-1H -isom dole-1,3(2H )-dione (4)
W hite pow dery crystals. Yield: 75% ; m p 157-158  °C ; TLC: R f =  0 .27 (S1); H PLC: tR =  0.906; 
M S calcd for [M +  H ]+: C20H 20N 2O3 m/z: 336.38, found: 337.14; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm 
2.76-2.87 (m, 6 H) 3.70 (s, 2 H) 3.88 (t, J  =  6.54 Hz, 2 H) 3.99 (s, 3 H) 6.96-7.02 (m, 1 H) 7.04-7.11 (m, 3 H) 
7.15 (d, J  =  8.46 H z, 1 H) 7.39 (d, J  =  7.44 Hz, 1 H) 7.61 (dd, J  =  8.46, 7.18 Hz, 1 H).
2-[2-(O ctahydroisoqum olm -2(1H )-yl)ethyl]-4-m ethoxy-1H -isom dole-1,3(2H )-dione (5)
C ream y pow dery crystals. Yield: 35% ; m p 145-146  °C; TLC: R f =  0.55 (S2); H PLC: tR =  1.124; 
M S calcd for [M +  H ]+: C20H26N 2O3 m/z: 342.43, found: 343.19; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm 
0 .79-1 .00  (m, 3 H) 1 .08-1 .30  (m , 4 H) 1.45-1 .71 (m , 6  H) 1 .94-2 .05  (m , 1 H ) 2.57 (t, J  =  7.05 H z, 2 H) 
2 .79-2 .86  (m, 1 H) 2.99 (d, J  =  10.77 H z, 1 H) 3.78 (t, J  =  7.05 H z, 2 H) 4.01 (s, 3 H) 7.18 (d, J  =  8.21 Hz, 
1 H) 7.42 (dd, J  =  7.31, 0.64 Hz, 1 H) 7.64 (dd, J  =  8.34, 7.31 Hz, 1 H).
2-[3-(6,7-D im ethoxy-3,4-dihydroisoqum olm -2(1H )-yl)propyl]-4-m ethoxy-1H -isom dole-1,3(2H )- 
dione (6 )
C ream y pow dery crystals. Yield: 39% ; m p 107-109  °C; TLC: R f =  0.38 (S2); H PLC: tR =  1.018; 
M S calcd for [M +  H ]+: C23H26N 2O5 m/z: 410.18, found: 411.18; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm
1.92 (quin, J  =  6 .86  H z, 2 H) 2 .53-2 .71  (m, 6  H) 3.45 (s, 2 H) 3 .72 -3 .84  (m, 8  H) 3.96 (s, 3 H ) 6.45 (d, 
J  =  5.90 H z, 2 H) 7.08 (d, J  =  8.46 Hz, 1 H) 7.35 (d, J  =  7.18 Hz, 1 H) 7.56 (dd, J  =  8.34, 7.31 Hz, 1 H).
2-[3-(3,4-D ihydroisoqum olm -2(1H )-yl)propyl]-4-m ethoxy-1H -isom dole-1,3(2H )-dione (7)
Yellow powdery crystals. Yield: 48%; mp 92-93 °C; TLC: R f =  0.32 (S2); HPLC: tR =  1.006; MS calcd 
for [M +  H]+: C21H22N 2O3 m/z: 350.41, found: 351.36; 1H -NM R (300 M Hz, CDCl3-d) 6 ppm 1.94 (quin, 
J  =  6.92 H z, 2 H) 2.58 (t, J  =  7.05 H z, 2 H) 2 .63 -2 .69  (m, 2 H) 2 .74-2 .81  (m, 2 H) 3.55 (s, 2 H) 3.77 
(t, J  =  6.92 H z, 2 H) 3.96 (s, 7 H) 3 .93-3 .99  (m , 3 H) 6 .92-7 .12  (m , 5 H) 7.36 (dd, J  =  7.18, 0.51 H z, 1 H) 
7.56 (dd, J  =  8.46, 7.18 Hz, 1 H).
2-[3-(O ctahydroisoqum olm -2(1H )-yl)propyl]-4-m ethoxy-1H -isom dole-1,3(2H )-dione (8 )
C ream y pow dery crystals. Yield: 46% ; m p 103-104  °C; TLC: R f =  0 .47 (S3); H PLC: tR =  1.161; 
M S calcd for [M +  H ]+: C21H 28N 2O3 m/z: 356.21, found: 357.21; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm 
0.78-0.93 (m, 3 H) 1.12-1.28 (m, 4 H) 1.43-1.71 (m, 6 H) 1.86-1.99 (m, 3 H) 2.48 (t, J  =  7.44 Hz, 2 H) 2.82 
(d, J  =  9.23 Hz, 1 H) 3.00 (d, J  =  11.03 Hz, 1 H) 3.69 (t, J  =  6.80 Hz, 2 H) 4.00 (s, 3 H) 7.17 (d, J  =  8.21 Hz, 
1 H) 7.40 (dd, J  =  7.31, 0.64 Hz, 1 H) 7.63 (dd, J  =  8.46, 7.18 Hz, 1 H).
2-Benzyl-4-m ethoxy-1H -isoindole-1,3(2H )-dione (9)
W hite pow dery crystals. Yield: 75% ; m p 167-168  °C ; TLC: Rf  =  0.70 (S1); H PLC: tR =  1.435; 
M S calcd for [M +  H ]+: C 16H 13N O 3 m/z: 267.09, found: 268.09; 1H -N M R  (300 M H z, C D C l3-d) 6 ppm
4.00 (s, 3 H) 4.81 (s, 2 H) 7.17 (d, J  =  7.95 Hz, 1 H) 7.21-7.33 (m, 3 H) 7.40-7.46 (m, 3 H) 7.64 (dd, J  =  8.46,
7.44 Hz, 1 H).
4-M ethoxy-2-(pyridm -2-ylm ethyl)-1H -isom dole-1,3(2H )-dione (10)
C ream y pow dery crystals. Yield: 53% ; m p 144-145  °C; TLC: R f =  0.56 (S2); H PLC: tR =  0.755; 
M S calcd for [M +  H ]+: C 15H 12N 2O3 m/z: 268.08, found: 269.09; 1H-N M R (300 M Hz, C D C l3-d) 6 ppm
4.00 (s, 3 H) 4.97 (s, 2 H) 7.10-7.17 (m, 1 H) 7.18-7.28 (m, 2 H) 7.46 (d, J  =  7.95 Hz, 1 H) 7.56-7.69 (m, 2 H) 
8.50 (dd, J  =  4.87, 2.56 Hz, 1 H).
2-(1H -Benzim idazol-2-ylm ethyl)-4-m ethoxy-1H -isoindole-1,3(2H )-dione (11)
C ream y pow dery crystals. Yield: 30% ; m p 2 3 9 -240  °C; TLC: R f =  0.34 (S3); H PLC: tR =  0.851; 
M S calcd for [M +  H ]+: C 17H 13N 3O3 m/z: 307.30, found: 308.29; 1H-N M R (300 M Hz, C D C l3-d) 6 ppm 
3.96 (s, 3 H) 5.14 (s, 2 H) 7.15 (d, J  =  8.46 Hz, 1 H) 7.18-7.28 (m, 3 H) 7.41 (dd, J  =  7.18, 0.51 Hz, 1 H) 7.63 
(dd, J  =  8.46, 7.44 Hz, 2 H).
4-M ethoxy-2-(2-phenylethyl)-1H -isoindole-1,3(2H )-dione (12)
W hite pow dery crystals. Yield: 43% ; m p 123-124  °C ; TLC: Rf  =  0.73 (S1); H PLC: tR =  1.533; 
M S calcd for [M +  H ]+: C 17H 15N O 3 m/z: 281.31, found: 282.05; 1H -N M R  (300 M H z, C D C l3-d) 6 ppm  
2.93-3.00 (m, 2 H) 3.85-3.92 (m, 2 H) 4.01 (s, 3 H) 7.15-7.32 (m, 6 H) 7.38-7.42 (m, 1 H) 7.63 (dd, J  =  8.46,
7.44 Hz, 1 H).
4-M ethoxy-2-[2-(pyridm -2-yl)ethyl]-1H -isom dole-1,3(2H )-dione (13)
C ream y pow dery crystals. Yield: 71% ; m p 155-157  °C; TLC: R f =  0.24 (S1); H PLC: tR =  0.797; 
M S calcd for [M +  H ]+: C 16H 14N 2O3 m/z: 282.10, found: 283.11; 1H-N M R (300 M Hz, C D C l3-d) 6 ppm
3.12-3.19 (m, 2 H) 4.00 (s, 3 H) 4.06 (dd, J  =  7.95, 6.67 Hz, 2 H) 7.08-7.20 (m, 3 H) 7.39 (dd, J  =  7 .31,0.64 
Hz, 1 H) 7 .52-7 .67 (m, 2 H) 8 .49-8 .53 (m, 1 H).
2-[2-(1H -Im idazol-4-yl)ethyl]-4-m ethoxy-1H -isoindole-1,3(2H )-dione (14)
W hite pow dery crystals. Yield: 30% ; m p 2 2 7 -228  °C ; TLC: R f =  0.14 (S2); H PLC: tR =  0.774; 
MS calcd for [M +  H]+: C 14H 13N 3O3 m/z: 271.27, found: 272.14; 1H-NM R (300 M Hz, DMSO-d6) 6 ppm 
2.81-2.88 (m, 2 H) 3.74 (t, J  =  6.80 Hz, 2 H) 3.92 (s, 3 H) 7.11 (s, 1 H) 7.33-7.47 (m, 2 H) 7.75 (dd, J  =  8.46,
7.44 Hz, 1 H) 8.24 (d, J  =  1.03 H z, 1 H).
2-[2-(1H -Benzim idazol-2-yl)ethyl]-4-m ethoxy-1H -isoindole-1,3(2H )-dione (15)
C ream y pow dery crystals. Yield: 40% ; m p 197-198  °C; TLC: R f =  0 .37 (S3); H PLC: tR =  0.871; 
M S calcd for [M +  H]+: C 18H 15N 3O3 m/z: 321.11, found: 322.31; 1H-NM R (300 M Hz, DMSO-d6) 6 ppm 
3.10 (t, J  =  7.33 Hz, 2 H) 3.89-3.98 (m, 5 H) 7.05-7.12 (m, 2 H) 7.37 (d, J  =  7.62 Hz, 1 H) 7.39-7.47 (m, 3 H)
7.72-7.79 (m, 1 H).
4-M ethoxy-2-(3-phenylpropyl)-1H -isoindole-1,3(2H )-dione (16)
W hite powdery crystals. Yield: 73%; mp 94-95 °C; TLC: R f =  0.80 (S1); HPLC: tR =  1.572; MS calcd 
for [M +  H ]+: C 18H 17N O 3 m/z: 295.21, found: 296.32; 1H -N M R  (300 M H z, C D C l3-d) 6 ppm  2.01 (dt, 
J  =  14.68, 7.66 Hz, 2 H) 2.62-2.71 (m, 2 H) 3.71 (t, J  =  7.18 Hz, 2 H) 4.01 (s, 3 H) 7.10-7.28 (m, 6 H) 7.41 
(dd, J  =  7.18, 0.51 Hz, 1 H) 7.64 (dd, J  =  8.34, 7.31 Hz, 1 H).
2-[3-(1H -Benzim idazol-2-yl)propyl]-4-m ethoxy-1H -isoindole-1,3(2H )-dione (17)
C ream y pow dery crystals. Yield: 45% ; m p 2 1 7 -218  °C; TLC: R f =  0 .37 (S2); H PLC: tR =  0.910; 
M S calcd for [M +  H ]+: C 19H 17N 3O3 m/z: 335.13, found: 336.34; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm
2.12-2.22 (m, 2 H) 2.88-2.96 (m, 2 H) 3.71-3.80 (m, 2 H) 4.06 (s, 3 H) 7.18-7.28 (m, 4 H) 7.47 (dd, J  =  7.31, 
0.64 Hz, 1 H) 7.59 (dd, J  =  5.51, 2.95 Hz, 1 H) 7.70 (dd, J  =  8.46, 7.44 Hz, 1 H).
2-[4-(1H -Benzim idazol-2-yl)butyl]-4-m ethoxy-1H -isoindole-1,3(2H )-dione (18)
C ream y pow dery crystals. Yield: 45% ; m p 6 9 -7 0  °C ; TLC: R f =  0.28 (S2); H PLC: tR =  1.002; 
C20H 19N 3O3 m/z: 349.14, found: 350.17; 1H-NM R (300 M Hz, C D C^-d) 6 ppm 1.67-1.92 (m, 4 H) 2.97 (t, 
J  =  7.33 H z, 2 H) 3.67 (t, J  =  6.74 H z, 2 H) 3.95 (s, 3 H ) 7 .12-7 .20  (m, 3 h )  7.37 (d, J  =  7.03 H z, 1 H) 7.
-7 .5 5  (m, 2 H) 7.61 (t, J  =  7.91 H z, 1 H); 13C -N M R  (75 M H z, C D C l3-d) 6 ppm  25.26, 27.83, 28 .27 ,36 .80 , 
56 .2 8 ,1 1 5 .4 6 ,1 1 7 .1 5 ,1 1 7 .5 2 ,1 2 2 .0 8 ,1 3 4 .0 9 ,1 3 6 .2 1 ,1 5 4 .5 1 ,1 5 6 .5 9 ,1 6 7 .3 6 ,1 6 8 .2 5 .
2-[5-(1H -Benzim idazol-2-yl)pentyl]-4-m ethoxy-1H -isoindole-1,3(2H )-dione (19)
C ream y pow dery crystals. Yield: 50% ; m p 108-109  °C; TLC: R f =  0.38 (S2); H PLC: tR =  1.072; 
M S calcd for [M +  H ]+: C21H 21N 3O3 m/z: 363.41, found: 364.12; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm 
1.32-1.46 (m, 2 H) 1.69 (quin, J  =  7.18 Hz, 2 H) 1.90 (dt, J  =  15.68, 7.69 Hz, 2 H) 2.91 (t, J  =  7.33 Hz, 2 H) 
3.64 (t, J  =  7.03 H z, 2 H ) 4.00 (s, 3 H) 7 .14-7 .21 (m , 3 H) 7.41 (d, J  =  7.03 H z, 1 H ) 7.53 (dd, J  =  5.86,
2.93 Hz, 2 H) 7.64 (dd, J  =  8.50, 7.33 Hz, 1 H); 13C-N M R (75 M H z, C D C l3-d) 6 ppm  26.07, 27.13, 28.03, 
29.00, 37.21, 5 6 .2 8 ,1 1 5 .4 3 ,1 1 7 .2 4 ,1 1 7 .4 7 ,1 2 2 .0 2 ,1 3 4 .1 7 ,1 3 6 .1 5 ,1 5 4 .7 3 ,1 5 6 .5 7 ,1 6 7 .3 5 ,1 6 8 .2 3 .
2-[2-(1H -Benzim idazol-2-yl)ethyl]-1H -isoindole-1,3(2H )-dione (20)
W hite pow dery crystals. Yield: 55% ; m p 2 0 2 -203  °C ; TLC: R f =  0.35 (S3); H PLC: tR =  0.827; 
M S calcd for [M +  H]+: C 17H 13N 3O2 m/z: 291.30, found: 292.06; 1H-NM R (300 M Hz, DMSO-d6) 6 ppm 
3.14 (t, J  =  7.33 Hz, 2 H) 4.00 (t, J  =  7.33 Hz, 2 H) 7.06-7.12 (m, 2 H) 7.38-7.46 (m, 2 H) 7.78-7.87 (m, 4 H).
2-[3-(1H -Benzim idazol-2-yl)propyl]-1H -isoindole-1,3(2H )-dione (21)
W hite pow dery crystals. Yield: 6 6 %; m p 190-191 °C ; TLC: R f =  0 .37 (S3); H PLC: tR =  0.869; 
M S calcd for [M +  H ]+: C 18H 15N 3O2 m/z: 305.12, found: 306.10; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm 
2.15-2 .27 (m, 2 H) 2.89-2 .98 (m, 2 H) 3.74-3.83 (m, 2 H) 7.17-7.25 (m, 2 H) 7.53-7.61 (m, 2 H) 7.71-7.78 
(m, 2 H) 7.82-7.89 (m, 2 H).
2-[4-(1H -Benzim idazol-2-yl)butyl]-1H -isoindole-1,3(2H )-dione (22)
C ream y pow dery crystals. Yield: 43% ; m p 179-180  °C; TLC: R f =  0.28 (S2); H PLC: tR =  1.001; 
M S calcd for [M +  H ]+: C 19H 17N 3O2 m/z: 319.13, found: 320.10; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm
1.73-1.94 (m, 4 H) 3.00 (t, J  =  7.33 Hz, 2 H) 3.75 (t, J  =  6.74 Hz, 2 H) 7.16-7.23 (m, 2 H) 7.49-7.58 (m, 2 H) 
7. -7 .74  (m, 2 H) 7.79-7 .86 (m, 2 H).
2-[5-(1H -Benzim idazol-2-yl)pentyl]-1H -isoindole-1,3(2H )-dione (23)
W hite pow dery crystals. Yield: 59% ; m p 168-169  °C ; TLC: R f =  0.30 (S2); H PLC: tR =  1.080; 
M S calcd for [M +  H ]+: C20H 19N 3O2 m/z: 333.15, found: 334.15; 1H -N M R (300 M Hz, C D C l3-d) 6 ppm 
1.37-1.50 (m, 2 H) 1.74 (quin, J  =  7.18 Hz, 2 H) 1.94 (dt, J  =  15.39, 7.84 Hz, 2 H) 2.93 (t, J  =  7.33 Hz, 2 H) 
3.70 (t, J  =  7.03 Hz, 2 H) 7.16-7.23 (m, 2 H) 7.54 (dd, J  =  5.86, 2.93 Hz, 2 H) 7.67-7.74 (m, 2 H) 7.79-7.86 
(m, 2 H).
3.2. Pharm acology
3.2.1. Protocols for M easuring PD E10A  Inhibition In Vitro
Test and reference compounds were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 
1 mM and further diluted in assay buffer in order to obtain the final concentration of compounds: 10 gM 
and 3 gM, respectively. All reactions were carried out at 37 °C in w hite, half-area 96-well plates (Perkin 
Elmer, Waltham, M A, USA). The inhibition of PDE 10A enzyme was measured using the PDElight HTS 
cAM P phosphodiesterase assay kit (Lonza) according to the m anufacturer's recom m endations. 2.5 U 
of PDE 10A enzym e w as preincubated either w ith  D M SO  (vehicle control) or com pound for 20 m in 
before incubation w ith  the substrate, cA M P (final concentration 1.25 gM ), for 1 h. Then, PD ELight 
A M P D etection R eagent w as added. A fter 10 m in incubation, the lum inescence w as m easured in a 
m ultifunction plate reader (POLARstar Omega, BMG Labtech, Ortenberg, Germany). The results were 
expressed as percent of inhibition or, for the m ost active com pounds selected, as the half m axim al 
inhibitory concentration values.
3.2.2. Radioligand Binding Studies
Radioligand binding studies w ith serotonin 5-HT1A and 5-H T7 receptors were conducted according 
to m ethods previously described [41,42], whereas percent of inhibition of the control binding for 5-H T2a  
and D 2 w ere perform ed according to protocols described online (w w w .cerep.fr). Briefly: binding 
experim ents w ere conducted in  96-w ell m icroplates in a total final volum e of 250 gL of appropriate 
buffers. Reaction mix included 50 gL solution of test compound, 50 gL of radioligand ([3H]8-OH-DPAT 
for 5 -H T1A, and [3H ]-LSD  for 5-H T7, respectively) and 150 gL of diluted m em branes (see description 
and Table S2 in  Supporting M aterials). Specific assay conditions for each receptor are described 
elsew here [41] . The radioactivity  w as m easured in  a M icroBeta2 scintillation counter (PerkinElm er, 
U SA ). E ach  com pound w as tested in the assay as duplicate sam ples at 1 gM  final concentrations. 
R esults w ere expressed as percent inhibition of specific binding.
3.3. M olecular M odeling
The phosphodiesterase 10A m odel was developed on the basis of the experimental structure of the 
enzyme (PDB ID: 3SNI) [43]. The structure was refined using default settings in the Protein Preparation 
W izard. W ater m olecules (except for the buried w ater m olecules) and hetero groups, other than the 
ligand, were deleted and the whole system w as m inim ized (OPLS3 force field). The model w as tested 
extensively w ith docking studies involving PDE 10A inhibitors. The resulting consistent binding modes 
of the reference com pounds of experim entally  proven affinity w ere used as the basis for verifying 
the accuracy of the m odel that served as m olecular target in docking studies. Ligand structures w ere 
optim ized u sing the LigPrep tool. The G lide SP flexible docking procedure w as carried out using 
default param eters. H -bond constraint, as w ell as centroid of a grid box, w ere located on Gln716.
G lide, LigPrep, and Protein Preparation W izard w ere im plem ented in the Sm all-M olecule D rug 




The HePG2 hum an liver cancer cell-line, (ATCC® 59195™ ) and the SH -SY5Y hum an neuroblastoma 
cell-line (ATCC® CRL-2266™ ) were used in the study. The cells were cultured in standard conditions 
(37 °C, 5% CO 2), in EM EM  (HepG2 and SH -SY5Y), supplem ented w ith 10% fetal bovine serum  (FBS) 
(Gibco, Therm o Fisher Scientific, W altham , MA. USA) and antibiotics (Lonza, Köln, Germ any).
3.4.2. C ytotoxicity Analysis— M TT
The M TT assay was used to determine the cytotoxic e ffects of the analyzed compounds. Cells were 
seeded at a density of 2 X 104 in 96-w ell plates. Follow ing overnight culture, cells w ere then treated 
w ith  increasing concentrations of com pound 18 (0 .1 -100  gM ) and incubated for 24 h. Follow ing 
cell exposure for 24 h, 10 gL M TT reagent (Sigm a A ldrich) w as added to each w ell and, after 3 h 
of incubation (37 °C , 5%  C O 2), the m edium  w as aspirated and the form azan produced in the cells 
appeared as dark crystals in the bottom  of the w ells. N ext, C rystal D M SO  w as added to each w ell. 
Then, the optical density (OD) of each w ell w as determ ined at 570 nm on a plate-reader (Spectra iD3, 
M olecular D evices, San Jose, CA, USA). The num ber of m etabolically active and living cells is directly 
proportional to the absorbance of the sam ples. The results are presented in Figure 5 as the percentage 
of control ±  SEM . D oxorubicin w as used as reference standard (cytotoxic agent).
3.5. In Vivo Studies
The experim ents w ere perform ed on m ale CD-1 m ice (in the accredited anim al facility  at the 
Jagiellonian  U niversity  M edical C ollege, Krakow , Poland), and m ice w ere kep t in  groups of ten in
M akrolon type 3 cages (dim ensions 26.5 X 15 X 42 cm). The anim als w ere kept in an environm entally 
controlled room  (am bient tem perature 22  ±  2  °C ; relative hum idity  50 -60% ; 12:12 light:dark cycle, 
lights on a t 8:00). They w ere allow ed to acclim atize w ith  the environm ent for one w eek before 
com m encem ent of the experim ents. Standard laboratory food (Ssniff M -Z) and filtered w ater w ere 
freely available. All the experim ental procedures w ere approved by the I Local Ethics Com m ission at 
the Jagiellonian U niversity in Krakow  (Approval N os.: 125/2017,123/2015, and 158/2017).
All the experiments were conducted in the light phase betw een 09.00 and 14.00 h. Each experimental 
group consisted of 7 -10  anim als per treatm ent dose. The anim als w ere used only once.
3.5.1. d-A m phetam ine-Induced H yperlocom otor A ctivity in CD-1 M ice
Locom otor activity w as recorded w ith an O pto M 3 m ulti-channel activity m onitor (M ultiD evice 
Software v.1.3, Columbus Instruments, Columbus, OH, USA). The CD-1 mice were individually placed 
in p lastic cages (22 X 12 X 13 cm ) im m ediately  after drug adm inistration, and then am bulation w as 
counted during 1 h  w ith  data recording every 10 m in. The cages w ere cleaned up w ith  70% ethanol 
after each m ouse.
3.5.2. Spontaneous Locom otor A ctivity in CD-1 M ice
Locom otor activity w as recorded according to the m ethod described above.
3.5.3. Drugs
The follow ing drugs w ere used: d-am phetam ine (sulfate, Sigm a-A ldrich , Poznań, Poland), 
papaverine (hydrochloride, Sigm a-Aldrich, Poznan, Poland), and tested compound 18. D-amphetamine 
and papaverine w ere d issolved in distilled w ater; the tested com pound (18) w as suspended in a 
1% aqueous solution of Tw een 80 im m ediately  before adm inistration. Papaverine and 18 w ere 
adm inistered intraperitoneally  (ip) and d-am phetam ine subcutaneously  (sc) ju st prior to the test 
starting. A ll com pounds w ere injected at a volum e of 10 m L/kg. C ontrol anim als received a vehicle 
injection according to the same schedule. Figure 6 shows only the doses at w hich the antipsychotic-like 
activity of AM PH , papaverine, and com pound 18 w ere observed.
3.5.4. Statistics
A ll the data are presented as the m ean ±  SEM . The statistical significance of the results w as 
evaluated by a one-w ay ANOVA, followed by a Bonferroni's C om parison Test.
4. C onclusions
In this study, we describe the synthesis of a library of novel 4-m ethoxy-2,3-dihydro-1H -isoindole-
1,3-dione derivatives w ith  various am inoalkyl m oieties, as potential inhibitors of P D E10A  and 
serotonin receptor ligands. A m ong the synthesized and tested com pounds, 1H -benzim idazole 
derivatives w ere identified as potent PD E10A  inhibitors. C om pound 18, the m ost potent PD E10 
inhibitor (IC 50 =  886  ±  0 .017 nM ) of the group, w ith  drug-like properties as defined by  Lipinski's 
Rule o f five, w as selected for further pharm acological evaluation. In  order to explain  its inhibitory 
activity tow ards PD E10A , the binding m ode of com pound 18 w as determ ined. M olecular m odeling 
studies show ed that H -bonds form ed by  the 4-m ethoxy group in  the phthalim ide m oiety  as w ell 
as the optim al length of the carbon linker are crucial for interactions w ith  PD E10A . Prelim inary 
in vitro neurotoxicity  and hepatotoxicity  studies revealed that the com pound is safe and did not 
exhibit notew orthy cytotoxicity. Furtherm ore, significant antipsychotic properties of 2-[4-(1H - 
benzim idazol-2-yl)butyl]-4-m ethoxy-1H -isoindole-1,3(2H )-dione (compound 18) w as identified in the 
d-AMPH-induced hyperlocom otor activity test in mice, but further pharmacological studies are needed 
to explain  the m echanism  u nderlying its antipsychotic activity. This study successfully  identified a
num ber of com pounds w ith significant PDE10A inhibitory activity and provided further inform ation 
into the m olecular basis of their interaction w ith PDE10A.
Supplementary Materials: The following are available online, Figure S1: The spider graph of drug-like parameters 
of compound 18, Figure S2. Effects of papaverine and compound 18 on d-amphetamme-mduced hyperlocomotor 
activity in CD-1 mice, Table S1: Effects of papaverine and compound 18 on spontaneous locomotor activity in 
CD-1 mice, Table S2. Detailed conditions of the in vitro binding assays for the 5-HT 1a  and 5-HT7 receptors and 
examples of NMR spectra.
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